Categories: Technology

Microvast Schedules Fourth Quarter Earnings Call

 | Source: Microvast Holdings, Inc.

STAFFORD, Texas, March 13, 2026 (GLOBE NEWSWIRE) — Microvast Holdings, Inc. (NASDAQ: MVST), (“Microvast” or the “Company”), a global leader in advanced battery technologies, will issue a press release reporting its consolidated financial results for the full year and fourth quarter of 2025 after market close on Monday, March 16, 2026.

Following the earnings press release, Microvast management will host a webcast and earnings conference call at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss the business results and outlook. The webcast will be accessible from the Events & Presentations section of Microvast’s investor relations website at https://ir.microvast.com. A replay will be available following the conclusion of the event.

About Microvast

Microvast is a global leader in providing battery technologies for electric vehicles and energy storage solutions. With a legacy of over 19 years, Microvast has consistently delivered cutting-edge battery systems that empower a cleaner and more sustainable future. The company’s innovative approach and dedication to excellence have positioned it as a trusted partner for customers around the world. Founded in 2006 in Stafford, Texas, Microvast holds more than 810 patents that enable solutions for today’s electrification needs.

For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).

Contact

Investor Relations
ir@microvast.com

GlobeNews Wire

Recent Posts

Stamus Networks Marks 10th Year Supporting NATO CCDCOE Cyber Defense Exercises

Company celebrates a decade of supporting the world's premier live-fire cyber defense exercises with expertise,…

42 minutes ago

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+…

3 hours ago

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed…

3 hours ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus…

3 hours ago

GIGABYTE Unveils Next-Generation Gaming Peripherals with AORUS K10 INFINITY Keyboard and M10 INFINITY Mouse at COMPUTEX 2026

TAIPEI, June 3, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation…

3 hours ago

Nationwide Celebrations mark Ruskin Bond’s 92nd Birthday

GURUGRAM, India, June 2, 2026 /PRNewswire/ -- On May 19, 2026, 92 bookstores across India…

9 hours ago